OBN Appoints Chair
This article was originally published in Scrip
OBN, the organization supporting UK's life sciences companies, has appointed Sally Waterman chair of OBN – effective immediately. Waterman succeeds David Laskow-Pooley who stepped down as chair after eight years and will continue as a non-executive director of OBN. Waterman joined OBN's board as a non-executive director in 2014 and is currently the senior vice president of corporate development at Abzena Plc.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.